Substantially reducing ketamine’s dissociative effects, thereby making a TRD treatment more accessible and improve patients’ lives.

The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma in Switzerland, and partnered with MEDICE for European commercialization, is an oral prolonged-release formulation of ketamine for Treatment-Resistant Depression (TRD).

Current ketamine-based treatments require patients to travel to a clinic and stay for hours under supervision, which is not possible for many people. Ketabon is designed for at-home use, making treatment easier to access and fit into patients’ lives.

The pharmacokinetic profile of this prolonged-release formulation could significantly improve the tolerability and patient accessibility, by minimizing dissociative effects compared with the currently applied intravenous and intranasal therapies.

TRD patients with insufficient response to standard antidepressants represent 30% of all patients suffering from MDD. In this group, our oral prolonged-release formulation of ketamine has shown good response rates.

HMNC Brain Health is advancing its investigational oral prolonged-release formulation of ketamine for the treatment of TRD toward Phase 3 readiness.

If you'd like to learn more about KET01 and how we're working to make it available to patients, please visit our website at www.ketabon.health There you can find more information about this promising treatment option.